Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer : promise, controversies and ambiguities in the novel treatment paradigm

Breimer, Lars H. ; Nousios, Petros ; Olsson, Louise and Brunnström, Hans LU orcid (2020) In Scandinavian Journal of Clinical and Laboratory Investigation 80(5). p.360-369
Abstract

Immune checkpoint inhibitors (ICIs) have received much attention not least for melanoma since the award of the Nobel prize in 2018. Here, we review the current state of knowledge about the use of these monoclonal antibodies (mAbs) in non-small cell lung cancer (NSCLC). These drugs have generally been conditionally approved on limited early data and there are few long-term follow-up data from randomized clinical trials. The effect observed for NSCLC thus far is, on average, moderately better than that obtained with chemotherapy. Severe side-effects are more common than might have been expected. The drugs themselves are expensive and are associated with time-consuming histopathologic testing even though the predictive value of these tests... (More)

Immune checkpoint inhibitors (ICIs) have received much attention not least for melanoma since the award of the Nobel prize in 2018. Here, we review the current state of knowledge about the use of these monoclonal antibodies (mAbs) in non-small cell lung cancer (NSCLC). These drugs have generally been conditionally approved on limited early data and there are few long-term follow-up data from randomized clinical trials. The effect observed for NSCLC thus far is, on average, moderately better than that obtained with chemotherapy. Severe side-effects are more common than might have been expected. The drugs themselves are expensive and are associated with time-consuming histopathologic testing even though the predictive value of these tests can be discussed. In addition, monitoring for side-effects involves increased workload and budgetary expense for clinical chemistry laboratories. Here, we review and summarize the current knowledge, controversies and ambiguities of ICIs for the treatment of NSCLC.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarkers, immune checkpoint inhibition, Non-small-cell lung carcinoma, PD-1/PD-L1, pharmaceutical economics
in
Scandinavian Journal of Clinical and Laboratory Investigation
volume
80
issue
5
pages
10 pages
publisher
Informa Healthcare
external identifiers
  • scopus:85082809536
  • pmid:32238062
ISSN
0036-5513
DOI
10.1080/00365513.2020.1742369
language
English
LU publication?
yes
id
6655c9d6-e0a5-4335-9c66-0786ac380195
date added to LUP
2020-04-27 16:15:22
date last changed
2024-06-12 13:47:27
@article{6655c9d6-e0a5-4335-9c66-0786ac380195,
  abstract     = {{<p>Immune checkpoint inhibitors (ICIs) have received much attention not least for melanoma since the award of the Nobel prize in 2018. Here, we review the current state of knowledge about the use of these monoclonal antibodies (mAbs) in non-small cell lung cancer (NSCLC). These drugs have generally been conditionally approved on limited early data and there are few long-term follow-up data from randomized clinical trials. The effect observed for NSCLC thus far is, on average, moderately better than that obtained with chemotherapy. Severe side-effects are more common than might have been expected. The drugs themselves are expensive and are associated with time-consuming histopathologic testing even though the predictive value of these tests can be discussed. In addition, monitoring for side-effects involves increased workload and budgetary expense for clinical chemistry laboratories. Here, we review and summarize the current knowledge, controversies and ambiguities of ICIs for the treatment of NSCLC.</p>}},
  author       = {{Breimer, Lars H. and Nousios, Petros and Olsson, Louise and Brunnström, Hans}},
  issn         = {{0036-5513}},
  keywords     = {{biomarkers; immune checkpoint inhibition; Non-small-cell lung carcinoma; PD-1/PD-L1; pharmaceutical economics}},
  language     = {{eng}},
  month        = {{04}},
  number       = {{5}},
  pages        = {{360--369}},
  publisher    = {{Informa Healthcare}},
  series       = {{Scandinavian Journal of Clinical and Laboratory Investigation}},
  title        = {{Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer : promise, controversies and ambiguities in the novel treatment paradigm}},
  url          = {{http://dx.doi.org/10.1080/00365513.2020.1742369}},
  doi          = {{10.1080/00365513.2020.1742369}},
  volume       = {{80}},
  year         = {{2020}},
}